-+ 0.00%
-+ 0.00%
-+ 0.00%

The Zhitong Finance App learned that EIR Biopharma is a pre-clinical biotechnology company dedicated to developing therapies for ophthalmic diseases introduced through authorization. The company withdrew its IPO plan on Monday. It submitted an application in February 2026 to sell 3.8 million shares at a price of 4 to 5 US dollars each, raising 17 million US dollars.

Zhitongcaijing·11/17/2026 06:49:08
Listen to the news
The Zhitong Finance App learned that EIR Biopharma is a pre-clinical biotechnology company dedicated to developing therapies for ophthalmic diseases introduced through authorization. The company withdrew its IPO plan on Monday. It submitted an application in February 2026 to sell 3.8 million shares at a price of 4 to 5 US dollars each, raising 17 million US dollars.